Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Obesity
Biotech
Kailera plans $528.5 million IPO to support obesity assets
Kailera plans to raise up to $528.5 million via a Nasdaq IPO, with proceeds intended to advance its GLP-1 assets through clinical development.
Will Maddox
Apr 13, 2026 1:10pm
ADCs, TCEs among ‘exciting things’ on Boehringer's shopping list
Apr 3, 2026 8:40am
Kailera plots IPO to fund Hengrui-licensed obesity pipeline
Mar 30, 2026 3:45am
Pulmatrix picked for reverse merger with anti-aging biotech
Mar 26, 2026 10:12am
Wave crashes after obesity trial tracks 1% dip in body weight
Mar 26, 2026 9:20am
BrightGene's oral drug sees up to 8% weight loss in early data
Mar 25, 2026 4:04am
